New Enterprise Associates

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the epigenome, the company aims to create new pathways for treatment without making changes to the DNA sequence itself. This approach allows for the potential development of therapies for complex and widespread medical conditions, positioning Tune Therapeutics at the forefront of advancements in the field of epigenetics.

Ouro Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic, immune-mediated illnesses. It specializes in integrating scientific knowledge and clinical trial experience to develop innovative, cell-depleting therapies. The company's core technology involves T cell engager antibodies that target and eliminate specific pathogenic cells, aiming to provide extended remissions for patients without the need for continuous immunosuppression.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

PayZen is a healthcare fintech startup founded in 2019 in San Francisco by Ariel Rosenthal, Itzik Cohen, and Tobias Mezger. The company addresses the challenge of patient payment responsibilities by providing a platform that allows patients to pay their out-of-pocket medical bills over time, enhancing convenience and transparency. PayZen's technology utilizes artificial intelligence to create tailored payment plans that cater to individual financial situations, thereby improving affordability for patients. This approach not only facilitates timely payments but also helps medical providers optimize cash flow and minimize the costs associated with collecting outstanding invoices. By focusing on patient financing solutions, PayZen enables healthcare providers to concentrate on delivering medical care rather than managing financial transactions.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

In-House Health is an AI-powered technical platform for modern nursing teams.

Zenas BioPharma is a clinical-stage biopharmaceutical company based in Florida, dedicated to developing immune-based therapies for patients. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody that targets both CD19 and FcγRIIb, which are found on B cells. This innovative approach aims to inhibit the activity of B cells involved in various autoimmune diseases while preserving their overall population, thus offering a potential therapeutic advantage over traditional treatments that deplete these cells.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Nexo Therapeutics is a biotechnology company focused on developing small-molecule therapies for cancer patients who have few effective treatment options. The company utilizes a specialized platform that integrates covalent ligand discovery with chemical biology to create innovative oncology drugs aimed at challenging targets that have been difficult to address in the past. By advancing its pipeline of novel therapies, Nexo Therapeutics seeks to provide new avenues for treatment, ultimately enhancing the care available to individuals battling cancer and other related diseases.

Spyglass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases, leveraging advanced technology to enhance patient care and vision. The company focuses on creating ophthalmic devices and a drug delivery platform that addresses unmet needs in areas such as cataracts and lens replacement surgeries. Its delivery system is designed to be implanted alongside intraocular lenses during standard cataract procedures, allowing surgeons to administer multi-year therapies for chronic conditions. This approach aims to improve the accessibility and affordability of quality eye treatments for patients, ensuring better outcomes in ophthalmic care.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

Launchpad Therapeutics is an antibody-focused precision oncology company that specializes in developing early mutant-selective antibodies to enhance cancer therapies. Utilizing artificial intelligence-driven programs, the company aims to create novel monoclonal antibodies, facilitating drug design, development, and testing for research purposes. This innovative approach provides medical professionals with new alternatives for cancer treatment, addressing the complexities of the disease through targeted therapeutic strategies.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Elion operates a digital health software marketplace that connects healthcare builders with a variety of software and service vendors through its online platform. The company provides comprehensive vendor listings, detailed product evaluations, and educational resources, allowing healthcare providers to research, compare, and select technology solutions tailored to improve their operations and enhance patient care. By facilitating informed technology decisions, Elion aims to support both startups and established organizations in delivering better healthcare outcomes.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Everside Health is a direct primary care provider founded in 2010 and based in Denver, Colorado. The company offers a range of services, including biometric screenings, health risk assessments, lifestyle coaching, and acute care, catering to patients across the nation. Everside's healthcare delivery model is data-driven and patient-centric, focusing on convenient on-site, near-site, and virtual care options. By aligning incentives among patients, physicians, and benefit providers, Everside aims to enhance patient engagement and overall health while simultaneously reducing the total cost of care.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Evernow is a provider of women's health care services focused on supporting women before, during, and after menopause. The company offers an online teleconsultation platform that connects users with specialized doctors and provides access to science-backed information and treatments. Through this platform, Evernow facilitates conversations about effective care for managing changing hormones, empowering women to lead longer and healthier lives.

Uniphore Software Systems Private Limited is a technology company that specializes in multilingual speech recognition software solutions focused on enhancing customer interactions. Founded in 2008 and headquartered in Chennai, India, with additional offices in Manila, Dubai, Palo Alto, and Singapore, Uniphore develops an integrated suite of software products that includes tools for conversational analytics, virtual assistance, and voice biometrics. Their offerings include auMina, a platform for transforming customer service through real-time conversation analysis, and akeira, an AI-enabled conversational assistant designed to enhance customer engagement. Uniphore caters to a diverse range of sectors such as banking, insurance, retail, healthcare, and government, enabling businesses to analyze conversations, improve customer service, and implement conversational security measures to prevent fraud. By leveraging natural language processing and sentiment analysis, Uniphore's solutions help organizations optimize their customer service operations and drive efficiency.

Nitra is a financial technology company focused on enhancing the healthcare industry through efficient and transparent solutions. The company offers a platform that provides machine learning-powered financial software, including credit cards, loans, accounts, payments, and expense management tailored for medical professionals. Nitra's tools help healthcare providers streamline their spending and manage payments in one centralized location, offering a clear overview of daily expenses. The Nitra Visa Business Card rewards users with benefits for every transaction and provides access to discounts through a network of partners. By simplifying accounting and receipt reconciliation, Nitra aims to support healthcare providers in balancing patient care with efficient practice management, delivering modern technology and dedicated support to the sector.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

InCarey is a comprehensive medical service platform based in Shanghai, China, founded in 2011. The company specializes in the management of patients with chronic and vertical diseases, integrating medical, pharmaceutical, and insurance resources to deliver a one-stop solution for long-term healthcare needs. Its cloud-based platform offers professional disease management services, facilitating one-on-one interactions between doctors and patients. Additionally, InCarey's e-commerce capabilities enable users to obtain medications for major diseases efficiently. The platform is designed to address the complexities of chronic disease management, providing innovative payment solutions and a streamlined approach to healthcare services.

Sorriso Pharmaceuticals is a biotechnology company based in San Diego, California, founded in 2020. The company focuses on developing disease-modifying antibodies aimed at treating inflammatory diseases such as Crohn's disease and ulcerative colitis. Sorriso's innovative platform produces potent antibodies that can be delivered orally, ensuring they remain effective throughout the intestinal system. This approach aims to provide clinical benefits comparable to traditional injectable antibody therapeutics, thereby alleviating the treatment burden for patients who typically rely on injections for their care. By advancing its pipeline of oral therapies, Sorriso Pharmaceuticals seeks to improve patient outcomes and enhance the management of inflammatory diseases.

Belong Health is a health insurance company focused on delivering Medicare Advantage and special needs plan products. The company collaborates with local health plans to provide regionally informed and compassionate care to a growing community. By partnering with these regional health plans, Belong Health aims to create a straightforward Medicare experience for eligible members, facilitating access to quality healthcare through trusted insurance partners. This approach allows Belong Health to launch or enhance market-leading plans that address the specific needs of its members.

Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the epigenome, the company aims to create new pathways for treatment without making changes to the DNA sequence itself. This approach allows for the potential development of therapies for complex and widespread medical conditions, positioning Tune Therapeutics at the forefront of advancements in the field of epigenetics.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Recludix Pharma is a biotechnology company focused on drug discovery, specifically targeting the development of potent and selective inhibitors for challenging protein targets associated with cancer and autoimmune diseases. The company utilizes a unique platform that combines custom-generated DNA-encoded libraries with massively parallel structure-activity relationship determination and proprietary screening tools. This integrated approach aims to enhance the identification and development of novel small molecule medicines, enabling healthcare professionals to create precision therapies that effectively address specific protein targets in these complex diseases.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Spiras Health operates a healthcare organization focused on delivering specialized treatment to patients with complex chronic conditions in their homes. The company employs a multidisciplinary team of clinicians to provide home-based clinical services, which are enhanced by telehealth, two-way digital communications, and remote patient monitoring. This approach aims to improve patients' quality of life while minimizing the costs associated with unnecessary hospitalizations. Spiras Health is dedicated to offering compassionate and specialized care tailored to the needs of each patient, ensuring they receive the support necessary to manage their health effectively in a familiar environment.

Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). The company has developed a platform that produces heterobifunctional small molecules, known as RESTORACS, which selectively recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins. This process enhances the stability and activity of these proteins. Stablix focuses on utilizing its innovative technology to create therapeutic programs aimed at treating rare diseases, cancer, and immunological disorders. By restoring protein function, Stablix aims to provide more effective treatment options for complex medical conditions.

Aetion, Inc. is a healthcare analytics company that specializes in real-world evidence (RWE) and outcomes-based analytics solutions. Founded in 2012 and based in New York City, Aetion develops the Aetion Evidence Platform, which leverages everyday clinical and financial interactions within the healthcare system to generate critical insights about the effectiveness and value of medical treatments. This platform serves a diverse clientele, including life sciences companies, payers, providers, medical device manufacturers, and academic institutions, allowing them to analyze data from various sources such as claims, electronic health records, registries, and clinical trials. Aetion’s patented rapid-cycle analytics technology facilitates real-time collaboration among stakeholders, enabling them to make informed decisions and optimize patient care. The company has formed strategic partnerships with leading organizations, including McKesson, to enhance its offerings and expand its reach in the healthcare sector.

Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Cleo is a family support system that employers offer working parents, by helping families navigate their journey from fertility, to pregnancy, to parenting of newborns, infants, toddlers, and children to age 5. Employers choose Cleo as a strategic partner to power their culture transformation and see increased employee retention, more diverse and inclusive workplaces, and reduced health claims. Cleo supports parents globally in 50+ countries and works with forward-thinking companies like eBay, LinkedIn, Uber, and Straus Family Creamery and many others. Cleo is headquartered in San Francisco and is backed by Felicis Ventures, Forerunner Ventures, Greylock Partners, and NEA. Learn more at hicleo.com.

Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing novel therapeutics for oncology and infectious diseases. The company focuses on targeting dysfunctional metabolic pathways, particularly through its expertise in fatty acid synthase (FASN) biology. Its lead drug candidate, denifanstat, is a selective FASN inhibitor designed for the treatment of nonalcoholic steatohepatitis (NASH) and is administered as an oral, once-daily pill. Additionally, Sagimet is working on antiviral therapeutics aimed at addressing respiratory syncytial virus, cytomegalovirus, and other human pathogens. Originally known as 3-V Biosciences, Inc., the company rebranded to Sagimet Biosciences in August 2019 and has been active since its incorporation in 2006.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Spyglass Ophthalmics, Inc. is a company focused on developing ophthalmic therapeutic devices aimed at enhancing vision and eye care for patients. Founded in 2019 and based in Mission Viejo, California, Spyglass addresses unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic conditions. By creating innovative devices, the company seeks to provide patients with quality eye treatment that is also affordable.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Resilience, established in 2020 and headquartered in La Jolla, California, is a biopharmaceutical manufacturing and technology company. It specializes in providing end-to-end manufacturing and development solutions for complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Resilience invests in developing new manufacturing technologies to ensure rapid, safe, and scalable production, thereby enhancing patient access to these treatments. The company partners with biopharmaceutical companies to focus on breakthrough discoveries while Resilience manages the manufacturing process, safeguarding supply chains against future disruptions.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Tempus, established in 2015 and based in Chicago, Illinois, is a technology company specializing in precision medicine. It develops a comprehensive library of molecular and clinical data, along with an operating system that makes this information accessible and useful for patients, physicians, and researchers. Tempus offers services such as genomic sequencing, clinical data restructuring, and biological modeling, enabling real-time data-driven decisions for personalized patient care and facilitating the discovery of optimized therapeutic options.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Evenly is a technology platform that specializes in orthodontics, aiming to enhance oral health and wellness through innovative solutions. Founded in 2019 and headquartered in Washington, D.C., the company leverages AI technology and 3D printing to deliver precise orthodontic treatments, including advanced Invisalign options. Its platform allows for remote treatment management, offering patients regular check-ins with orthodontists and clinical experts. By integrating these technologies, Evenly seeks to improve the overall patient experience and accessibility to high-quality orthodontic care across the country.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing novel therapeutics for oncology and infectious diseases. The company focuses on targeting dysfunctional metabolic pathways, particularly through its expertise in fatty acid synthase (FASN) biology. Its lead drug candidate, denifanstat, is a selective FASN inhibitor designed for the treatment of nonalcoholic steatohepatitis (NASH) and is administered as an oral, once-daily pill. Additionally, Sagimet is working on antiviral therapeutics aimed at addressing respiratory syncytial virus, cytomegalovirus, and other human pathogens. Originally known as 3-V Biosciences, Inc., the company rebranded to Sagimet Biosciences in August 2019 and has been active since its incorporation in 2006.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Tempus, established in 2015 and based in Chicago, Illinois, is a technology company specializing in precision medicine. It develops a comprehensive library of molecular and clinical data, along with an operating system that makes this information accessible and useful for patients, physicians, and researchers. Tempus offers services such as genomic sequencing, clinical data restructuring, and biological modeling, enabling real-time data-driven decisions for personalized patient care and facilitating the discovery of optimized therapeutic options.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Spyglass Ophthalmics, Inc. is a company focused on developing ophthalmic therapeutic devices aimed at enhancing vision and eye care for patients. Founded in 2019 and based in Mission Viejo, California, Spyglass addresses unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic conditions. By creating innovative devices, the company seeks to provide patients with quality eye treatment that is also affordable.

THE WELL is a membership-based wellness club and spa located in New York City, catering to busy urban professionals. The organization integrates both Western medicine and Eastern healing practices to create a comprehensive health ecosystem. It offers personalized wellness plans developed collaboratively by integrative medicine doctors, health coaches, and skilled practitioners. The focus is on whole-person care, enabling members to take an active role in their health through tailored consultations and customized experiences. By combining modern medical insights with traditional healing wisdom, THE WELL empowers its community to maintain their health and well-being effectively.